AR+/ER+ Breast Cancer
Deep dive on androgen-receptor-positive, estrogen-receptor-positive breast cancer, including AR-dominant biology, enobosarm logic, resistance questions, and monitoring ideas
The AR+/ER+ pattern sits inside ER-positive, HER2-negative breast cancer.
It matters most when AR looks biologically important, not just incidentally positive.
That often means high AR expression, lower or moderate ER dominance, or apocrine differentiation.
Jump menu
Understanding your receptor profile
Most hormone-receptor discussions centre on estrogen.
That can miss an important second receptor.
That receptor is the androgen receptor, or AR.
Around 90% of ER-positive breast cancers also express AR.
The important question is not simple AR positivity.
The real question is whether AR is functionally dominant.
In some ER-positive tumours, strong AR signalling may partly restrain ER-driven growth.
That is why this subgroup deserves its own treatment logic.
AR+/ER+ is not a separate formal subtype in the same way as HER2-positive or triple-negative.
It is a useful clinical shorthand for a subgroup of ER-positive disease where AR may be biologically important.
The pleomorphic lobular and apocrine subtype
This topic is especially relevant in tumours with apocrine differentiation.
That includes rare settings such as invasive pleomorphic lobular carcinoma with apocrine differentiation.
These tumours often show very strong AR expression.
The pathology may also reflect an androgen-led biology.
Markers worth noticing include:
AR staining level
GCDFP-15
FOXA1
apocrine morphology on the pathology report
When these features cluster together, AR is more likely to matter biologically.
How the androgen receptor can act as a tumour suppressor in ER-positive disease
This is the key concept.
AR and ER both depend on transcriptional helper proteins.
Two important ones are p300 and SRC-3.
When AR is strongly activated in the right context:
AR can pull these coactivators away from ER
ER loses some ability to drive growth-promoting genes
ER can be displaced from some of its DNA binding sites
proliferation markers like Ki67 may fall
tumour growth may slow
This is why some researchers now describe AR as a tumour suppressor in part of ER-positive disease.
The stronger the AR expression, the more plausible this effect becomes.
That is one reason why AR staining level matters so much in this discussion.
The two opposite treatment strategies
This is the main practical fork.
AR-targeted therapy can mean two very different things.
AR antagonists
Examples include enzalutamide and bicalutamide.
These block AR signalling.
That approach makes the most sense in AR-driven, ER-negative disease.
It is most relevant in the luminal androgen receptor form of triple-negative breast cancer.
AR agonists
The main drug here is enobosarm.
This activates AR instead of blocking it.
That is the more biologically coherent approach when:
the tumour is ER-positive
AR is strongly expressed
the goal is to let AR suppress ER output
The key idea is simple.
The same receptor may need blocking in one subtype and activating in another.
That is why AR antagonists and agonists are not interchangeable.
Enobosarm: what it is and what the evidence shows
Enobosarm is a selective androgen receptor modulator.
It is also called ostarine or GTx-024.
It is designed to activate AR with more tissue selectivity than standard androgen exposure.
What the clinical data suggest
A Phase II trial studied enobosarm in AR-positive, ER-positive, HER2-negative advanced breast cancer.
The study reported:
measurable anti-tumour activity
better benefit when AR expression was higher
acceptable tolerability in the study setting
a strong separation between high-AR and low-AR tumours
The most important signal was biomarker-driven.
Patients with higher AR staining did much better than those with lower staining.
That supports a selection strategy, not broad use.
Why this is still early
Enobosarm is still in the investigational clinical trial stage in breast cancer.
It is not standard of care.
It should be discussed through:
a clinical trial
a molecular tumour board
or a clinician-led access pathway where available
The bacterial microbiome connection
This part of the story is interesting, but less settled.
Emerging papers suggest that gut and tumour microbiota may influence hormone handling, immune tone, and treatment response.
Several ideas are being explored:
some gut bacteria may alter estrogen and androgen metabolism
beta-glucuronidase activity may reactivate hormone metabolites
Fusobacterium nucleatum may contribute to more aggressive breast-cancer behaviour
oral and periodontal health may matter more than once assumed
This does not mean microbiome theories should drive treatment by themselves.
It does mean microbiome and oral-health issues are worth taking seriously.
The most defensible takeaways are practical ones:
address periodontal disease
investigate chronic dental infection properly
keep microbiome claims evidence-aware
treat more specific intervention claims with caution
Monitoring for resistance: realistic markers for patients
If AR-targeted logic is being discussed, resistance planning matters from the start.
One emerging concern is a possible switch toward JAK/STAT signalling with prolonged AR activation.
This remains an evolving research area.
It is not yet a routine clinical rule.
Still, it gives a useful framework for what to watch.
Blood-based discussion points
Markers worth asking about can include:
IL-6 as a direct upstream inflammatory signal relevant to JAK/STAT
CRP as a crude downstream inflammatory marker
ctDNA to look for evolving resistance patterns if metastatic monitoring is already being considered
If progression leads to re-biopsy
These changes may matter:
rising Ki67
falling ER expression
loss of apocrine or luminal markers such as GCDFP-15 or FOXA1
more aggressive histology or lineage shift
tissue evidence of pSTAT3 if specifically requested
The point is not to over-test.
The point is to have a resistance plan before a promising strategy starts to fail.
Integrative support considerations:
reviewing oral health and periodontal status
considering whether chronic dental infection needs better imaging or specialist review
keeping gut health, bowel function, and microbiome diversity in view during endocrine therapy
asking whether a baseline IL-6 level is worth adding for context
using stool or microbiome testing cautiously, as supportive rather than decisive data
The goal here is to tighten the broader terrain around treatment.
It is not to replace pathology, imaging, or systemic oncology decisions.
L. reuteri yoghurt as an oral-microbiome intervention
A more specific supportive idea is worth considering.
Limosilactobacillus reuteri is among the better-studied probiotic species for oral-pathogen displacement.
The main interest here is its possible effect against Fusobacterium nucleatum.
The proposed mechanisms are multi-layered:
Physical coaggregation: L. reuteri can bind directly to F. nucleatum and help pull it out of the biofilm community
Competitive exclusion: it can occupy oral adhesion sites and gradually displace pathogenic species
Reuterin production: it produces antimicrobial compounds that may work against Gram-negative anaerobes
Biofilm disruption: it may interfere with the acid-tolerance and persistence programs that help oral pathogens rebuild biofilm
The overall logic is ecological, not drug-like.
It is about shifting the oral microbial balance over time.
That means consistency matters more than single doses.
If this is discussed with the care team, the main practical points are:
oral delivery matters most
lozenges or slow oral exposure make more sense than simply swallowing capsules
repeated exposure through the day is more logical than one isolated dose
a two-week trial window is a reasonable minimum for looking for a shift in oral ecology
A practical model is three-times-daily oral exposure through lozenge or yoghurt-rinse style use.
That is a plausible practical model for an oral-biofilm goal.
It should still be framed as a supportive strategy, not a proven oncology intervention.
L. Reuteri in Oncology Guide
For more detailed strain, preparation, and safety notes, see the companion guide:
L. Reuteri in Oncology: A Deep Dive for Cancer Patients
Dental-source caution
This question becomes more relevant when there is:
a history of root canal treatment
chronic gum disease
unexplained dental symptoms
concern for a persistent oral anaerobic reservoir
If there is genuine concern about chronic dental infection, proper dental review matters more than probiotics alone.
That may include:
targeted dental assessment
CBCT imaging when standard dental imaging has been unrevealing
review by a dentist who is comfortable thinking in oral-systemic terms
If a periapical abscess or failed root canal is confirmed, source control matters.
An oral probiotic cannot clear a sealed deep dental infection by itself.
Triple-negative breast cancer
This ER-positive logic does not carry across directly to triple-negative disease.
In high-AR triple-negative breast cancer, the more relevant strategy is often AR blockade, not AR activation.
HER2-positive disease
There is no established clinical role for enobosarm in HER2-positive breast cancer.
That includes patients previously treated with HER2-directed therapy.
For now, AR activation in HER2-positive disease remains too uncertain to treat as a parallel strategy.
Key questions for your oncologist
Is my tumour strongly AR-positive, or only weakly AR-positive?
Does my pathology suggest apocrine differentiation or another AR-dominant pattern?
In my case, does AR look more like a receptor to activate or block?
Would enzalutamide be biologically sensible here, or could it work against the goal?
Are there any suitable enobosarm studies or access pathways?
Should my pathology be reviewed for GCDFP-15, FOXA1, or repeat AR scoring?
Would ctDNA be useful for baseline or resistance monitoring?
If progression happens, should repeat biopsy be part of the next-step plan?
Should my case be reviewed by a molecular tumour board because of the receptor mix or rare histology?
Master reference list
Hickey TE, et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nature Medicine. 2021. DOI: 10.1038/s41591-020-01168-7
Asemota S, Effah J. A molecular switch from tumor suppressor to oncogene in ER+ breast cancer: role of androgen receptor, JAK-STAT, and lineage plasticity. PNAS. 2024. DOI: 10.1073/pnas.2406837121
Overmoyer B, et al. Activity and safety of enobosarm in androgen receptor-positive, estrogen receptor-positive, HER2-negative advanced breast cancer. Lancet Oncology. 2024. DOI: 10.1016/S1470-2045(24)00004-4
Gucalp A, et al. Phase II trial of bicalutamide in androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clinical Cancer Research. 2013. DOI: 10.1158/1078-0432.CCR-12-3327
Elebro K, et al. Relationship between androgen receptor and androgen receptor-related markers in breast carcinoma with apocrine differentiation. Scientific Reports. 2025. DOI: 10.1038/s41598-025-87403-y
Ricciardelli C, et al. Pharmacological targeting of androgen receptor elicits context-dependent effects in breast cancer. Cancer Research. 2023. DOI: 10.1158/0008-5472.CAN-22-1686
Arruza Ibarra A, et al. Arming androgen receptors to oppose oncogenic estrogen receptor activity. npj Breast Cancer. 2021. DOI: 10.1038/s41523-021-00295-7
Chu D, et al. Modulating the activity of androgen receptor for treating breast cancer. Frontiers in Endocrinology. 2022. PMC8717192
Terrisse S, et al. Impact of microbiota on breast cancer hormone therapy. Cell Stress. 2023. DOI: 10.15698/cst2023.03.279
Gur C, et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nature Communications. 2020. DOI: 10.1038/s41467-020-16967-2
Shi L, et al. Endocrine-targeting therapies shift the breast microbiome to reduce tumour-promoting bacteria. Cell Reports Medicine. 2024. DOI: 10.1016/j.xcrm.2024.101815
Nejman D, et al. Interactions between the tumor microbiota and breast cancer. Frontiers in Cellular and Infection Microbiology. 2025. DOI: 10.3389/fcimb.2024.1499203
Shi L, et al. Fusobacterium nucleatum promotes metastasis of breast cancer via CXCL-10 pathway. Frontiers in Oncology. 2025. PMC12206713
Momen-Heravi F, Babic A. The role of oral Fusobacterium nucleatum in female breast cancer. Frontiers in Microbiology. 2022. PMID: 36466367
Pham VT, et al. Limosilactobacillus reuteri DSM 17938 inhibition of Fusobacterium nucleatum biofilm formation in vitro. 2024. PMC11750330
Teles F, et al. Limosilactobacillus reuteri–Fusobacterium nucleatum interactions and competitive exclusion. Journal of Periodontal Research. 2025. DOI: 10.1111/jre.70021
Guo R, et al. Lactobacillus reuteri biofilms inhibit pathogens and regulate host immunity. Journal of Agricultural and Food Chemistry. 2022. DOI: 10.1021/acs.jafc.2c02372
Limosilactobacillus reuteri inhibits the acid tolerance response in oral biofilm bacteria. 2023. PMC10319175
Fusobacterium in the microbiome: from health to disease across the body. npj Biofilms and Microbiomes. 2025. DOI: 10.1038/s41522-025-00838-z
Sharma D, et al. How bacteria promote breast cancer. Cell Communication and Signaling / Johns Hopkins reporting. 2026.